** Specialty pharma firm 60 Degrees Pharmaceuticals' SXTP.O shares rise 5.6% to 63 cents in afternoon trade

** Company says the FDA does not object to co's plan to import anti-malaria drug from Australia against any near-term disruption in the U.S.

** Arakoda is an antimalarial drug for the prophylaxis of malaria in patients aged 18 years and older in the U.S.

** The drug is sold under the brand name Kodatef in Australia

** The drug is not approved for use in the U.S.

** SXTP plans to import a five-month supply of Kodatef while increasing manufacturing of Arakoda over long term

** Co says the two products are identical in their dosing regimens, mechanisms of action, safety and efficacy profiles, and other clinical features

** In the last 12 months, stock has fallen 80.2%

(Reporting by Siddhi Mahatole)

((Siddhiprabhanjan.mahatole@thomsonreuters.com))